In this video, we explore the exciting progress made by Moderna and Merck in developing personalized cancer vaccines using mRNA technology. The midstage trial results show that the vaccine, in combination with Merck's immunotherapy Keytruda, helped prevent relapse for high-risk melanoma patients, with a significantly higher percentage of patients alive and cancer-free at 18 months compared to immunotherapy alone.
Moderna's vaccine is tailored to each patient, analyzing their tumor for mutations and selecting up to 34 targets to incorporate into a vaccine. This vaccine could be a game-changer in cancer treatment, and the companies plan to expand their research to other tumor types.
While the development of effective cancer vaccines is still in its early stages, recent advances in technology and research offer great promise in the fight against cancer.
#cancer #cancertreatment #cancervaccine #melanoma #immunotherapy #Keytruda #mrnavaccine
